Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4468-4476
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4468
Effects of invigorating-spleen and anticancer prescription on extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway in colon cancer mice model
Wei Wang, Jing Wang, Xiu-Xiu Ren, Hai-Long Yue, Zheng Li
Wei Wang, Zheng Li, Department of Integrated Traditional Chinese and Western Medicine Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, Liaoning Province, China
Jing Wang, Xiu-Xiu Ren, Hai-Long Yue, The First Clinical School, Liaoning University of Chinese Medicine, Shenyang 110847, Liaoning Province, China
Co-first authors: Wei Wang and Jing Wang.
Author contributions: Li Z conceived the work, supervised the writing, and provided intellectual input; Wang W and Wang J were responsible for most of the manuscript; All authors conducted the literature search.
Supported by Liaoning Provincial Science and Technology Department Project, No. 2023JH2/101700149; and Open Fund Project of Liaoning University of Traditional Chinese Medicine, No. zyzx2205.
Institutional animal care and use committee statement: All animal husbandry and experiments were conducted in strict accordance with the regulations for the care and use of laboratory animals, approved by the Institutional Animal Care and Use Committee of the Liaoning University of Chinese Medicine, No. 2021012125.
Conflict-of-interest statement: All authors state that they have no conflicts of interest to report.
Data sharing statement: All authors agree data sharing, and available from the Corresponding author by request at oabqddc@163.com.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Zheng Li, MD, Chief Physician, Department of Integrated Traditional Chinese and Western Medicine Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, China. fox_dl1984@163.com
Received: August 6, 2024
Revised: September 6, 2024
Accepted: September 29, 2024
Published online: November 15, 2024
Processing time: 80 Days and 1.9 Hours
Core Tip

Core Tip: The incidence and mortality of intestinal cancer is increasing year by year. Due to the limited therapeutic means and low survival rate of advanced patients, and the easy development of drug resistance to chemotherapy, targeting and immunotherapy, we have found that spleen-healthy anticancer formula can play an anti-tumor role through the extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling pathway and inhibit the expression of matrix metalloproteinase 2 and c-myc.